REG - Haleon PLC - Update on off-market purchase alongside Pfizer

HALEONAnnouncement

19/03/2025 07:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250319:nRSS2729Ba&default-theme=true

RNS Number : 2729B  Haleon PLC  19 March 2025

 

Haleon plc: Update on off-market purchase alongside Pfizer Inc. offering

 

19 March 2025: Further to its announcement on 18 March 2025, Haleon plc (the
"Company" or "Haleon") (LSE/NYSE: HLN) has agreed to make an off-market
purchase of 44,155,844 ordinary shares of £0.01 each of the Company from
Pfizer Inc. ("Pfizer") pursuant to the terms of the share purchase deed
entered into between Haleon and Pfizer that was previously approved by
Haleon's shareholders.

 

The off-market purchase is being made in conjunction with, and subject to the
completion of an offering by Pfizer to institutional investors, the results of
which have been announced by Pfizer today. The purchase price payable by
Haleon to Pfizer for the off-market purchase is £3.85 per ordinary share and
the total consideration payable will be approximately £170 million.

 

The off-market purchase represents a portion of the £500 million allocated to
share buybacks in 2025 announced on 27 February 2025. The purchased ordinary
shares will be cancelled.

 

On completion of the off-market purchase and Pfizer's offering to
institutional investors, Pfizer's interest in Haleon's issued ordinary shares
with voting rights is expected to reduce from approximately 7.3% to nil.

Brian McNamara, Chief Executive Officer of Haleon commented: "Today's
transaction is an important milestone for the business and marks Pfizer fully
exiting its stake in Haleon, having been at 32% at the time of demerger in
July 2022. Our participation in the offering is consistent with our
disciplined capital allocation priorities, and supports our commitment to
deliver attractive returns for shareholders, underpinned by a strong
investment grade balance sheet. Nearly three years on from demerger, Haleon is
in a position of strength and is well placed to capitalise on the significant
opportunities ahead."

The Company will make a further announcement upon completion of the off-market
purchase.

Amanda Mellor

Company Secretary

 

Enquiries

 

 Investors                                    Media

 Jo Russell              +44 7787 392441      Zoë Bird            +44 7736 746167
 Rakesh Patel            +44 7552 484646      Victoria Durman     +44 7894 505730
 Emma White              +44 7823 523562

 Email: investor-relations@haleon.com         Email: corporate.media@haleon.com

 

About Haleon

Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose
to deliver better everyday health with humanity. Haleon's product portfolio
spans five major categories - Oral Health, Pain Relief, Respiratory Health,
Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its
long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren, Theraflu,
Otrivin, Polident, parodontax and Centrum - are built on trusted science,
innovation and deep human understanding.

 

For more information please visit www.haleon.com (http://www.haleon.com)

 

 

Not for release, publication or distribution in the United States, Canada,
Japan, Australia or any other state or jurisdiction in which such release,
publication or distribution would be unlawful.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDGLGDXUXBDGUC